

# World Journal of *Gastroenterology*

*World J Gastroenterol* 2019 October 7; 25(37): 5578-5731



**MINIREVIEWS**

- 5578** Pathogenesis and clinical management of *Helicobacter pylori* gastric infection  
*de Brito BB, da Silva FAF, Soares AS, Pereira VA, Santos MLC, Sampaio MM, Neves PHM, de Melo FF*

**ORIGINAL ARTICLE****Basic Study**

- 5590** Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer  
*Wei L, Wen JY, Chen J, Ma XK, Wu DH, Chen ZH, Huang JL*

**Case Control Study**

- 5604** Correlation of plasma miR-21 and miR-93 with radiotherapy and chemotherapy efficacy and prognosis in patients with esophageal squamous cell carcinoma  
*Wang WT, Guo CQ, Cui GH, Zhao S*

**Retrospective Cohort Study**

- 5619** Accuracy of an administrative database for pancreatic cancer by international classification of disease 10<sup>th</sup> codes: A retrospective large-cohort study  
*Hwang YJ, Park SM, Ahn S, Lee JC, Park YS, Kim N*

- 5630** Post-transplant infection improves outcome of hepatocellular carcinoma patients after orthotopic liver transplantation  
*Chao JS, Zhao SL, Ou-yang SW, Qian YB, Liu AQ, Tang HM, Zhong L, Peng ZH, Xu JM, Sun HC*

**Retrospective Study**

- 5641** Short-term efficacy of robotic and laparoscopic spleen-preserving splenic hilar lymphadenectomy via Huang's three-step maneuver for advanced upper gastric cancer: Results from a propensity score-matched study  
*Wang JB, Liu ZY, Chen QY, Zhong Q, Xie JW, Lin JX, Lu J, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Zheng HL, Que SJ, Zheng CH, Huang CM, Li P*
- 5655** Estimating survival benefit of adjuvant therapy based on a Bayesian network prediction model in curatively resected advanced gallbladder adenocarcinoma  
*Geng ZM, Cai ZQ, Zhang Z, Tang ZH, Xue F, Chen C, Zhang D, Li Q, Zhang R, Li WZ, Wang L, Si SB*
- 5667** Soluble mannose receptor as a predictor of prognosis of hepatitis B virus-related acute-on-chronic liver failure  
*Li TP, Guan SH, Wang Q, Chen LW, Yang K, Zhang H*

**Observational Study**

- 5676** Nonalcoholic fatty liver disease in patients with inflammatory bowel disease: Beyond the natural history  
*Magri S, Paduano D, Chicco F, Cingolani A, Farris C, Delogu G, Tumbarello F, Lai M, Melis A, Casula L, Fantini MC, Usai P*

**Prospective Study**

- 5687** Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging  
*Affonso BB, Galastri FL, da Motta Leal Filho JM, Nasser F, Falsarella PM, Cavalcante RN, de Almeida MD, Felga GEG, Valle LGM, Wolosker N*

**META-ANALYSIS**

- 5702** Is there an association between *Helicobacter pylori* infection and irritable bowel syndrome? A meta-analysis  
*Ng QX, Foo NX, Loke W, Koh YQ, Seah VJM, Soh AYS, Yeo WS*
- 5711** Is total laparoscopic pancreaticoduodenectomy superior to open procedure? A meta-analysis  
*Zhang H, Lan X, Peng B, Li B*

**ABOUT COVER**

Editorial board member of *World Journal of Gastroenterology*, Mortada HF El-Shabrawi, MD, FAASLD, Professor, Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo 11559, Egypt

**AIMS AND SCOPE**

The primary aim of *World Journal of Gastroenterology* (WJG, *World J Gastroenterol*) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online.

WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

**INDEXING/ABSTRACTING**

The WJG is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2019 edition of Journal Citation Report® cites the 2018 impact factor for WJG as 3.411 (5-year impact factor: 3.579), ranking WJG as 35<sup>th</sup> among 84 journals in gastroenterology and hepatology (quartile in category Q2). CiteScore (2018): 3.43.

**RESPONSIBLE EDITORS FOR THIS ISSUE**

Responsible Electronic Editor: *Yu-Jie Ma*

Proofing Production Department Director: *Yun-Xiaojuan Wu*

**NAME OF JOURNAL**

*World Journal of Gastroenterology*

**ISSN**

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

**LAUNCH DATE**

October 1, 1995

**FREQUENCY**

Weekly

**EDITORS-IN-CHIEF**

Subrata Ghosh, Andrzej S Tarnawski

**EDITORIAL BOARD MEMBERS**

<http://www.wjgnet.com/1007-9327/editorialboard.htm>

**EDITORIAL OFFICE**

Ze-Mao Gong, Director

**PUBLICATION DATE**

October 7, 2019

**COPYRIGHT**

© 2019 Baishideng Publishing Group Inc

**INSTRUCTIONS TO AUTHORS**

<https://www.wjgnet.com/bpg/gerinfo/204>

**GUIDELINES FOR ETHICS DOCUMENTS**

<https://www.wjgnet.com/bpg/GerInfo/287>

**GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH**

<https://www.wjgnet.com/bpg/gerinfo/240>

**PUBLICATION MISCONDUCT**

<https://www.wjgnet.com/bpg/gerinfo/208>

**ARTICLE PROCESSING CHARGE**

<https://www.wjgnet.com/bpg/gerinfo/242>

**STEPS FOR SUBMITTING MANUSCRIPTS**

<https://www.wjgnet.com/bpg/GerInfo/239>

**ONLINE SUBMISSION**

<https://www.f6publishing.com>



## Pathogenesis and clinical management of *Helicobacter pylori* gastric infection

Breno Bittencourt de Brito, Filipe Antônio França da Silva, Aline Silva Soares, Vinícius Afonso Pereira, Maria Luísa Cordeiro Santos, Mariana Miranda Sampaio, Pedro Henrique Moreira Neves, Fabrício Freire de Melo

**ORCID number:** Breno Bittencourt de Brito (0000-0002-1831-7909); Filipe Antônio França da Silva (0000-0002-0550-1109); Aline Silva Soares (0000-0003-1647-4035); Vinícius Afonso Pereira (0000-0001-6387-490X); Maria Luísa Cordeiro Santos (0000-0001-7078-9789); Mariana Miranda Sampaio (0000-0002-8531-963X); Pedro Henrique Moreira Neves (0000-0001-7410-277X); Fabrício Freire de Melo (0000-0002-5680-2753).

**Author contributions:** All authors equally contributed to this paper with conception and design of the study, literature review and analysis, drafting and critical revision and editing, and final approval of the final version; All authors agree to be accountable for all aspects of the work in ensuring that questions that related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Conflict-of-interest statement:** All authors declare no potential conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially,

Breno Bittencourt de Brito, Filipe Antônio França da Silva, Aline Silva Soares, Vinícius Afonso Pereira, Maria Luísa Cordeiro Santos, Mariana Miranda Sampaio, Pedro Henrique Moreira Neves, Fabrício Freire de Melo, Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Vitória da Conquista 45029-094, Bahia, Brazil

**Corresponding author:** Fabrício Freire de Melo, PhD, Postdoctoral Fellow, Professor, Instituto Multidisciplinar em Saúde, Universidade Federal da Bahia, Rua Hormindo Barros, 58, Quadra 17, Lote 58, Vitória da Conquista 45029-094, Bahia, Brazil. [freiremelo@yahoo.com.br](mailto:freiremelo@yahoo.com.br)  
**Telephone:** +55-77-991968134

### Abstract

*Helicobacter pylori* (*H. pylori*) is a gram-negative bacterium that infects approximately 4.4 billion individuals worldwide. However, its prevalence varies among different geographic areas, and is influenced by several factors. The infection can be acquired by means of oral-oral or fecal-oral transmission, and the pathogen possesses various mechanisms that improve its capacity of mobility, adherence and manipulation of the gastric microenvironment, making possible the colonization of an organ with a highly acidic lumen. In addition, *H. pylori* presents a large variety of virulence factors that improve its pathogenicity, of which we highlight cytotoxin associated antigen A, vacuolating cytotoxin, duodenal ulcer promoting gene A protein, outer inflammatory protein and gamma-glutamyl transpeptidase. The host immune system, mainly by means of a Th1-polarized response, also plays a crucial role in the infection course. Although most *H. pylori*-positive individuals remain asymptomatic, the infection predisposes the development of various clinical conditions as peptic ulcers, gastric adenocarcinomas and mucosa-associated lymphoid tissue lymphomas. Invasive and non-invasive diagnostic methods, each of them with their related advantages and limitations, have been applied in *H. pylori* detection. Moreover, bacterial resistance to antimicrobial therapy is a major challenge in the treatment of this infection, and new therapy alternatives are being tested to improve *H. pylori* eradication. Last but not least, the development of effective vaccines against *H. pylori* infection have been the aim of several research studies.

**Key words:** *Helicobacter pylori*; Virulence factors; Immune response; Antibiotics; Vaccines

and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Invited manuscript

**Received:** June 15, 2019

**Peer-review started:** June 17, 2019

**First decision:** July 21, 2019

**Revised:** August 14, 2019

**Accepted:** August 19, 2019

**Article in press:** July 21, 2019

**Published online:** October 7, 2019

**P-Reviewer:** Amiri M, Day AS, Gazouli M, Ierardi E, Talebi Bezin Abadi A

**S-Editor:** Yan JP

**L-Editor:** Filipodia

**E-Editor:** Ma YJ



©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** *Helicobacter pylori* (*H. pylori*) is a bacterium that infects more than half of the world's population. The mechanisms of such infections are complex and deeply studied. In addition, the clinical outcomes are variable and depend on both pathogen and host characteristics. Moreover, the adequate clinical management by means of proper diagnosis and effective treatment is crucial for reaching success in bacterial eradication. This article aims to provide a broad overview of *H. pylori* infection, from pathogenesis to clinical management.

**Citation:** de Brito BB, da Silva FAF, Soares AS, Pereira VA, Santos MLC, Sampaio MM, Neves PHM, de Melo FF. Pathogenesis and clinical management of *Helicobacter pylori* gastric infection. *World J Gastroenterol* 2019; 25(37): 5578-5589

**URL:** <https://www.wjgnet.com/1007-9327/full/v25/i37/5578.htm>

**DOI:** <https://dx.doi.org/10.3748/wjg.v25.i37.5578>

## INTRODUCTION

*Helicobacter pylori* (*H. pylori*) is a gram-negative bacterium that inhabits the gastric environment of more than half of the world population<sup>[1]</sup>. Studies have demonstrated that the prevalence of *H. pylori*-positive status varies according to different factors such as age, geographical area, living condition and socioeconomic status<sup>[2]</sup>. Oral-oral transmission seems to be the main route of *H. pylori* transmission. This explains the common occurrence of the infection among members of the same family, such as parents and children. In this way, the sharing of utensils during feeding seems to be important for infection establishment<sup>[3]</sup>. Fecal-oral transmission is another form of infection that occurs through ingestion of contaminated water mainly due to unsatisfactory basic sanitation conditions<sup>[4]</sup>. Therefore, it is important to highlight that increasing socioeconomic status and the improvement of living conditions are factors that greatly influence the reduction in *H. pylori* infection prevalence<sup>[5]</sup>.


Until Warren and Marshall's discovery of *H. pylori* infection in gastric mucosa, it was believed that the gastric environment was sterile because of its high acidity<sup>[6,7]</sup>. Aiming for successful colonization under such hostile conditions, the bacterium uses a wide range of mechanisms that provide improved mobility, robust adherence to epithelial cells and an enzymatic apparatus that allows the establishment of an appropriate microenvironment for infection perpetuation<sup>[8-10]</sup>. In addition, the potential of pathogenicity of this infection is provided by certain virulence factors such as cytotoxin associated antigen A (CagA), vacuolating cytotoxin (VacA), duodenal ulcer promoting gene A protein (DupA), outer inflammatory protein (OipA) and gamma-glutamyl transpeptidase (GGT)<sup>[11-15]</sup>. Moreover, the host immune system plays a crucial role in the course of the infection, likely by means of a Th1-polarized response against the pathogen (Figure 1)<sup>[16]</sup>.

Although most *H. pylori*-positive individuals are asymptomatic, such infections predispose the development of diseases like peptic ulcers and gastric adenocarcinomas<sup>[17]</sup>. In this way, proper clinical management with a well-made diagnosis followed by effective treatment are important steps in the improvement of a patient's clinical outcome<sup>[18]</sup>. A variety of invasive and non-invasive diagnostic methods have been used for *H. pylori* detection and, regarding treatment, bacterial resistance represents a major challenge in infection eradication<sup>[19,20]</sup>. In this sense, new therapy regimens as well as probiotic implementation have been tried in order to improve treatment results<sup>[21,22]</sup>. Moreover, the efforts of several researchers have been directed towards the development of vaccines against *H. pylori* infection.

## PATHOGENESIS

### Colonization

*H. pylori* successful colonization of the hostile gastric environment requires special mechanisms. Firstly, after reaching the gastric environment, *H. pylori* uses its crucial flagellar motility for swimming in gastric content, what allows the bacterium to get in the gastric mucus layer<sup>[8]</sup>. Four to eight sheathed flagella compose the flagellar group



**Figure 1 Aspects of *Helicobacter pylori* infection.** CagA: Cytotoxin associated antigen A; VacA: Vacuolating cytotoxin; DupA: Duodenal ulcer promoting gene A protein; OipA: Outer inflammatory protein; GGT: Gamma-glutamyl transpeptidase; TLRs: Toll-like receptors.

situated on a single or on both poles of the bacterium<sup>[23-25]</sup>. *H. pylori* flagella can also provide different movements according to the media in which the bacterium is located. In liquid media, it presents a “swimming motility”, whereas in soft agar and on the surface of solid media, “spreading” and “swarming” movements can be observed, respectively<sup>[25]</sup>. Various studies have shown that several mutations in genes that encode specific flagellar proteins such as fliD, FlaA and FlaB impair the proper motility of *H. pylori*, which can reduce or even cease its capacity to colonize the gastric mucosal layer<sup>[26-28]</sup>.

Besides flagella, *H. pylori* mobility also depends on chemotactic action in response to different molecules, such as mucin, sodium bicarbonate, urea, sodium chloride and some specific amino acids<sup>[29,30]</sup>. At least ten *H. pylori* genes are related to reception, signal transduction, and processing of chemotactic stimuli<sup>[31]</sup>. Different *H. pylori* chemoreceptors have been described: TlpA, B, C, and D, CheA kinase and various coupling proteins. These proteins are all crucial for bacterium colonization, as demonstrated by various studies over recent years<sup>[32]</sup>.

In addition, some transition metals are essential for living organisms, as they serve as cofactors for enzymatic reactions and some physiological processes, especially for enzymes that carry out the genetic material replication and transcription, attenuation of oxidative stress, and cellular energy production. In bacteria, these metals are crucial for survival and successful infection<sup>[33]</sup>. Nickel is an indispensable metal for *H. pylori*, since it is the cofactor for two important enzymes: urease and hydrogenase. These enzymes have a strong role in the infection process<sup>[10]</sup>. The activity of *H. pylori* urease contributes to the colonization of the microorganism, once this enzyme catalyzes the hydrolysis of urea to carbon dioxide and ammonia, which are buffer substances that attenuate the acidity of the stomach environment<sup>[34]</sup>. In turn, hydrogenase is part of a signaling cascade that induces an alternative airway, allowing *H. pylori* to use molecular hydrogen as a source of energy for its metabolism<sup>[35]</sup>.

Adhesion molecules (Table 1) and surface receptors of gastric cells are also important in the interaction between bacteria and host<sup>[9,36]</sup>. One of the most well-characterized molecules is the blood group antigen binding adhesin A (BabA), which carries out specific binding to Lewis H-1 antigens<sup>[37,38]</sup>. Bacteria with high BabA expression are more virulent, and cause duodenal ulcer and gastric adenocarcinoma pathogenesis<sup>[39]</sup>. Recently, another bacterial-host interaction was identified through the adhesion of the outer membrane Hp HopQ. These adhesins bind to the CEACAMs (cell adhesion molecules related to the carcinoembryonic antigen) 1, 3, 5 and 6. That binding gives rise to cell signaling mediated by the HopQ-CEACAM interaction, which allows the translocation of CagA, the main virulence factor of *H. pylori*, thus increasing proinflammatory mediators in the host cell<sup>[40-42]</sup>.

Table 1 *H. pylori* adhesion molecules

Adhesin	Functions	Ref.
BabA	Specific binding to the b and H-1 Lewis antigens from the surface of the gastric epithelial cells	[105]
SabA	Binding to Le <sup>x</sup> , which is upregulated in gastric epithelial cells by <i>H. pylori</i> after initial colonization mediated by BabA. Also allows the adherence of the bacterium to laminin, an extracellular matrix protein	[106,107]
AlpA and AlpB	Mediation of adherence to gastric mucosal cells and promotion of inflammatory intracellular signaling cascades (might induce IL-8 and IL-6)	[108]
OipA	Adhesion to the gastric mucosa cells and promotion of proinflammatory environment (associated with IL-8 increase, mucosal damage and duodenal ulcer)	[109]
HopQ	Interaction with CEACAM family proteins of gastric mucosal cells, allowing CagA translocation. Might inhibits the activity of natural killer cells and T cells	[110]
HopZ	Interaction with undetermined receptors, promoting adhesion to gastric cells	[111]

*H. pylori*: *Helicobacter pylori*; CagA: Cytotoxin associated antigen A; IL: Interleukin; BabA: Binding adhesin A; OipA: Outer inflammatory protein.

### CagA

CagA is a bacterial protein that induces specific modifications in the morphology of epithelial cells while altering cell polarity, leading to a “hummingbird” phenotype. Changes in cytoskeleton associated with the development of gastric adenocarcinoma can also be triggered by this virulence factor<sup>[43]</sup>. The *CagA* gene is contained in a *cag* pathogenicity island, a region that also possesses the coding sequence of a type IV secretion system (T4SS)<sup>[11]</sup>. This bacterial structure is responsible for performing the translocation of CagA, as well as peptidoglycans, into host cells<sup>[44]</sup>. Within the host cell, CagA undergoes tyrosine phosphorylation at a Glu-Pro-Ile-Tyr-Ala (EPIYA) motif, a variable C-terminal CagA region that can be composed by different EPIYA segments (EPIYA-A, EPIYA-B, EPIYA-C and EPIYA-D)<sup>[45]</sup>. EPIYA-A and EPIYA-B segments have been found in most *cagA*-positive *H. pylori* strains, while EPIYA-C and EPIYA-D segments are related to Western and Eastern strains, respectively<sup>[46]</sup>. *H. pylori* strains containing EPIYA-D or at least two EPIYA-C segments in its *cagA* gene are associated with a higher risk of cancer development<sup>[47]</sup>. In addition, Queiroz *et al*<sup>[48]</sup> demonstrated in a Brazilian population that first-degree relatives of patients with gastric cancer tend to be infected by *H. pylori* strains containing two or more EPIYA-C segments. After phosphorylation, CagA activates SHP-2 (SH2-containing protein-tyrosine phosphatase), which promotes the cell changes mentioned above<sup>[49]</sup>.

### Non-CagA virulence factors

Other various virulence factors have been related to an increased *H. pylori* capacity to impair gastric homeostasis. Among them, VacA is a determinant protein for *H. pylori* pathogenicity, and its gene is present in almost all bacterial strains. VacA promotes the formation of acidic vacuoles in the cytoplasm of gastric epithelial cells. Consequently, the integrity of mitochondria, cytoplasmic membrane, and endomembranous structures is destabilized, leading cells to collapse<sup>[50]</sup>. Moreover, this protein might also promote the activation and suppression of the immune response, inducing immune tolerance and persistent *H. pylori* infection through its activities on T-cells and antigen-presenting cells<sup>[51]</sup>. The set of changes performed by this virulence factor adds to enhanced gastritis, as well as to ulcer and cancer development<sup>[12]</sup>.

Another bacterial protein, DupA, seems to provide a higher acid resistance to the bacterium, and also might promote an increase in the production of IL-8 in the antral gastric mucosa. Enhanced IL-8 levels lead to mucosal inflammation and polymorphonuclear leukocyte infiltration, which contributes to the emergence of gastritis and duodenal ulcers<sup>[13]</sup>. Interestingly, the relation between *dupA*-positive *H. pylori* strains and duodenal ulcers has been observed in Asian countries, but not in the Western population<sup>[52]</sup>. Furthermore, our group demonstrated that the presence of functional *dupA* in *H. pylori* strains has been considered as a protective factor for gastric carcinoma development<sup>[53]</sup>. The gene products of *dupA* are homologues of the

VirB4 ATPase, which is related to the mounting of the secretion apparatus, however, the probable association of *dupA* with *H. pylori* T4SS still needs to be better elucidated<sup>[13]</sup>.

OipA, an outer membrane protein, contributes to both adhesion and increased inflammation by inducing enhanced IL-8 production<sup>[54,55]</sup>. The discovery of the relationship between OipA and the increased development of peptic ulcers and gastric cancer resulted in a larger number of studies on this *H. pylori* virulence factor<sup>[14]</sup>. The functional status of OipA has been described as an important factor in the outcome of the infection, since the expression of the *oipA* gene is regulated by a repair process called “slipped strand mispairing”, which depends on the quantity of CT dinucleotide repeats in the *oipA* 5' region. Such a process determines whether *oipA* is nonfunctional or functional in a given bacterial strain, and the latter condition is related to increased gastric pathogenicity<sup>[56,57]</sup>. In addition, OipA might be related to changes in  $\beta$ -catenin signaling, cell proliferation and reduction of cell-cell junctions<sup>[58]</sup>.

The enzyme GGT is a N-terminal nucleophile hydrolase also produced by *H. pylori* that catalyzes the conversion of glutamine into glutamate and ammonia, as well as the hydrolysis of glutathione into glutamate and cysteinylglycine<sup>[15]</sup>. Its activity leads to the production of reactive oxygen species (ROS), which, like ammonia, induce cell-cycle arrest, apoptosis and necrosis<sup>[59,60]</sup>. In addition, studies have demonstrated that this enzyme inhibits T cell proliferation and dendritic cell differentiation<sup>[61,62]</sup>. Higher GGT activity has been observed in peptic ulcer patients when compared to individuals with other gastroduodenal diseases<sup>[63]</sup>.

### Immunologic aspects

Complex host immune responses, embracing innate and adaptive mechanisms, are induced by *H. pylori* infection<sup>[64,65]</sup>. Given the initial contact with the pathogen, various *H. pylori* antigens such as lipoteichoic acid, lipoproteins, lipopolysaccharide, HSP-60, NapA, DNA, and RNA bind to gastric cell receptors, including toll-like receptor (TLR) 1, TLR2, TLR4, TLR5, TLR6, and TLR10 located on epithelial cell membranes, and TLR9, found in intracellular vesicles<sup>[66,67]</sup>. Such interaction promotes, among other signaling pathways, NF- $\kappa$ B and c-jun N-terminal kinase activation, followed by proinflammatory cytokine release<sup>[68]</sup>. Besides receptor activation by pathogen-associated molecular patterns, injection of CagA through T4SS also leads to the production of cytokines, in another NF- $\kappa$ B-dependent process<sup>[69]</sup>.

Subsequently, gastric mucosa is infiltrated by neutrophils and mononuclear cells, resulting in the production of nitric oxide and ROS<sup>[70]</sup>. Moreover, CD4+ and CD8+ T cells, components of adaptive immunity, are also recruited. A preferential activation of CD4+ cells to the detriment of CD8+ cells might occur, and a specific response is directed to the bacterium<sup>[71]</sup>. Regarding general cytokine profiles in *H. pylori*-positive patients, studies have suggested a Th1-polarized response, characterized by scarce IL-4 (a Th2 cytokine) and enhanced levels of gamma interferon, tumor necrosis factor, IL-1 $\beta$ , IL-6, IL-7, IL-8, IL-10, and IL-18<sup>[72,73]</sup>. With the exception of IL-10, which seems to play a role in limiting the inflammatory response, other increased cytokines might promote proinflammatory effects during *H. pylori* infection. Furthermore, we demonstrated that an increase in IL-17 is also associated with *H. pylori* infection, especially in adults<sup>[74]</sup>. In regard to immunoglobulin production, *H. pylori*-specific serum IgM antibodies can be detected in patient serum 4 wk after infection<sup>[75]</sup>. In chronic infection, serum IgA and IgG immunoglobulins are directed toward several bacterial antigens<sup>[76,77]</sup>. Such inflammation is asymptomatic in most *H. pylori*-positive patients, however it increases the risk of duodenal and gastric ulcer disease, as well as gastric malignancy development<sup>[78]</sup>.

## CLINICAL MANAGEMENT

### Clinical manifestations and diagnosis

As a consequence of the mechanisms explained above, *H. pylori*-positive individuals are under increased risk of presenting various clinical manifestations<sup>[17]</sup>. The course of infection is variable and strongly dependent on host factors. Besides this, the pattern of gastric mucosal involvement is correlated with the risk of initiation and progression of different gastric disorders. Development of antral-predominant gastritis is associated with duodenal ulcers, while a corpus-predominant gastritis and multifocal atrophy tend to turn into gastric ulcers, gastric atrophy, intestinal metaplasia and gastric carcinoma<sup>[79]</sup>. Among gastrointestinal conditions, dyspepsia and peptic ulcer disease are frequently observed in clinical practice, and bacterial detection, when it is present, followed by infection eradication are crucial steps in the management of such disorders<sup>[80]</sup>. In addition, recent studies have associated *H. pylori*

infection with a wide range of diseases. The infection was linked with the pathophysiology of neurological, dermatological, hematologic, cardiovascular, ocular, metabolic, hepatobiliary and allergic diseases<sup>[81]</sup>.

Various diagnostic tests, with their specific advantages and disadvantages, are offered for *H. pylori* detection. Histology is the precursor method for *H. pylori* infection diagnosis, which, in such a technique, consists in the observation of typical bacteria associated with inflammatory reactions in the tissue slides. This method includes the use of several stains, such as Giemsa staining, and immunostaining to allow pathogen detection<sup>[19]</sup>. Another important *H. pylori* diagnostic method, the rapid urease test (RUT), detects an increase in reagent pH after the addition of a biopsy specimen containing *H. pylori* to the reagent. Such pH variation is caused by the conversion of the urea test reagent into ammonia. RUT is a relatively cheap, quick, easy, specific and widely available test<sup>[82]</sup>. Polymerase chain reaction (PCR) has also been applied for *H. pylori* detection. Al-Moayad *et al.*<sup>[83]</sup> concluded that standardized PCR allows an accuracy superior to that observed in RUT, with improved detection in specimens with lower bacterial charge<sup>[84]</sup>. However, the necessity of endoscopy is an important limitation of the three methods mentioned above, and the advances in non-invasive diagnostic techniques have strengthened the idea of prioritizing the use of diagnostic alternatives for which endoscopy is dispensable.

The urea breath test (UBT) is now the main non-invasive method for such a diagnosis, gradually taking the place of RUT as the most suitable method for *H. pylori* detection. This test is based on the mechanism of bacterium degradation of <sup>13</sup>C or <sup>14</sup>C-labeled urea into CO<sub>2</sub>, which can be measured in the exhaled air using a mass or infrared spectrometer<sup>[85]</sup>. A Brazilian study<sup>[86]</sup> evaluated the use of a locally manufactured isotope in UBT, trying to reduce the importation costs of this substance, which is considered a limitation for the performance of this method in many countries. The assay concluded that the substrate manufactured in Brazil with reduced costs had similar performance when compared to the one imported from foreign countries. Such a reduction in the costs of this substrate can contribute to the dissemination of UBT use around the world.

A less expensive option for UBT, stool antigen tests (SATs), are good alternatives for *H. pylori* diagnosis. SATs can be made by means of enzyme immunoassay or immuno-chromatography<sup>[87]</sup>. In addition, a new promising non-invasive method, the urine test for the diagnosis of *H. pylori* infection, has been largely studied as an alternative. A meta-analysis from 2017<sup>[88]</sup>, which included 23 studies, showed that testing for antibodies in urine samples might be a good diagnostic option. However, further studies are necessary to confirm the accuracy of this method. Finally, new strategies for serologic diagnosis of *H. pylori* infection have been developed through the discovery of specific serological markers. A recent study evaluated the accuracy of the “hook-associated protein 2 homologue”, FliD, as a marker of this infection. The use of the FliD ELISA method in the detection of *H. pylori* infection provided high specificity (99%) and sensibility (97%). Moreover, this method presents a simple technique at low cost<sup>[89]</sup>.

### Treatment

There is not a universally accepted regimen for the treatment of *H. pylori* infection. However, all of them target the regressing symptomatology and healing of the mucosa damaged by the infection process<sup>[20]</sup>. Since the 1997 Mastricht consensus, the standard triple therapy with proton pump inhibitors (PPI) in standard dose, clarithromycin (500 mg), and amoxicillin (1 g) twice daily for 7 d have been employed in most countries as a first-line regimen to eradicate *H. pylori*. The quadruple therapy, with addition of bismuth (120 mg) to the regimen, has also been used as a first-line regimen<sup>[90]</sup>. However, the increase in microbial resistance to clarithromycin, whose prevalence varies with time and geographic region, is leading to changes in the therapeutic regimen. The indiscriminate use of azithromycin and erythromycin in the treatment of respiratory infections and cross-resistance among macrolide antibiotics may be responsible for the increased microbial resistance to clarithromycin<sup>[91]</sup>. As a consequence, longer therapeutic regimens have been used for *H. pylori* eradication<sup>[92]</sup>. In areas with high clarithromycin resistance, the addition of metronidazole (500 mg) concomitantly with PPI, clarithromycin and amoxicillin twice daily for 5 d, characterizing a quadruple therapy, improves the efficacy of the treatment, with an intention-to-treat higher than 90%<sup>[21]</sup>. Moreover, in regions with clarithromycin resistance above 15%-20%, and quinolone resistance below 10%, clarithromycin could be substituted by levofloxacin (250/500 mg) in triple therapy. Such exchange increases the per-protocol and intention-to-treat eradication rates of the treatment<sup>[21,93]</sup>. In addition, the use of hybrid therapy has been suggested as an alternative to the standard approaches in some countries. This therapeutic scheme consists of administering PPI and amoxicillin for 14 d, and then adding both clarithromycin and

nitroimidazole as a quadruple therapy for the final 7 d<sup>[94]</sup>. Finally, faced with such a situation, studies have proposed the use of tailored therapy as a possible new first-line treatment. Conducting tests for identifying the susceptibility of the bacterial strains to the different regimens appears to be a great alternative for bacterial eradication<sup>[95]</sup>.

Probiotics are being used in the prevention and treatment of many gastrointestinal infections, so it is strongly believed that they might be useful for the treatment of *H. pylori* infection<sup>[20]</sup>. Research about the use of probiotics for this purpose are typically divided into treatments with and without antibiotics, and data available in the literature are still controversial<sup>[96]</sup>. Zagari *et al*<sup>[97]</sup> showed that probiotic supplementation did not improve either the efficacy or tolerability of the treatment, regardless of the species of microorganism used. On the other hand, some studies suggest that probiotics help in the restoration of the intestinal microbiota disturbed by antibiotics, leading to a decrease in side effects and, consequently, increased adherence to treatment, corroborating successful therapy<sup>[98]</sup>. However, no effect has been observed against *H. pylori* infection using treatment with probiotics alone. Other studies claim that the use of probiotics in combination with antimicrobial therapy has a potentiating effect by increasing eradication rates; however, the relationship with adverse effects is still uncertain<sup>[99]</sup>. The beneficial effects of probiotics on this infection may be associated with immunological and non-immunological mechanisms, such as substance production, gastric mucosal strengthening, and regulation of immune function<sup>[100]</sup>. As seen, the role of probiotics in this infection eradication is not well-established and consolidated, and the use of different species of microorganisms, doses and research methods contribute to such uncertainties.

### Vaccines

The development of vaccines is a promising alternative that targets the prophylaxis and/or the treatment of the infection (Table 2)<sup>[101]</sup>. Recently, studies have focused on the development of reverse vaccines with the help of bioinformatics, and five antigenic epitopes have been prioritized as potential vaccine candidates: babA, sabA, fecA, vacA and omp16<sup>[20]</sup>. However, their development has been a major challenge in the *H. pylori* field, since many studies have not been successful in experimental models. In contrast, a randomized phase 3 study with children has been conducted in China, which was efficacious and safe in providing oral vaccines with recombinant B urease against *H. pylori*<sup>[102]</sup>. However, a more accurate evaluation of its long-term effect is required. In another study by Wang *et al*<sup>[103]</sup>, intramuscular administration was compared with oral administration of the multi-epitope vaccine, evidencing a better protection rate by oral administration. The development of nanovaccines is also being explored, and presents a nice potential to become an excellent alternative in triggering an effective immunological response against *H. pylori* infection<sup>[90,104]</sup>.

## CONCLUSION

Although the knowledge about the different *H. pylori* infection characteristics have been expanded since its discovery, much still needs to be done for a broader understanding of its underlying mechanisms. Furthermore, the new diagnostic methods should be better explored in order to reduce health expenditure and to provide less invasive diagnostic alternatives to patients. Finally, the growing resistance of *H. pylori* to antimicrobial therapy alerts to the necessity of developing satisfactory strategies for bacterial eradication, as well as vaccine implementation aiming at reducing infection prevalence.

Table 2 Preliminary effects of developing vaccines against *Helicobacter pylori* infection

Vaccine	Prophylactic	Therapeutic
EpiVax/ <i>Helicobacter pylori</i> vaccine	Yes	Yes
Helicovaxor®	Yes	No
Imevax/IMX101	Yes	No
Wuhu Kangwei Biological Technology	Yes	No

## REFERENCES

- 1 Alzahrani S, Lina TT, Gonzalez J, Pinchuk IV, Beswick EJ, Reyes VE. Effect of *Helicobacter pylori* on gastric epithelial cells. *World J Gastroenterol* 2014; **20**: 12767-12780 [PMID: 25278677 DOI: 10.3748/wjg.v20.i36.12767]
- 2 Peleteiro B, Bastos A, Ferro A, Lunet N. Prevalence of *Helicobacter pylori* infection worldwide: A systematic review of studies with national coverage. *Dig Dis Sci* 2014; **59**: 1698-1709 [PMID: 24563236 DOI: 10.1007/s10620-014-3063-0]
- 3 Urita Y, Watanabe T, Kawagoe N, Takemoto I, Tanaka H, Kijima S, Kido H, Maeda T, Sugawara Y, Miyazaki T, Honda Y, Nakanishi K, Shimada N, Nakajima H, Sugimoto M, Urita C. Role of infected grandmothers in transmission of *Helicobacter pylori* to children in a Japanese rural town. *J Paediatr Child Health* 2013; **49**: 394-398 [PMID: 23560808 DOI: 10.1111/jpc.12191]
- 4 Goh KL, Chan WK, Shiota S, Yamaoka Y. Epidemiology of *Helicobacter pylori* infection and public health implications. *Helicobacter* 2011; **16** Suppl 1: 1-9 [PMID: 21896079 DOI: 10.1111/j.1523-5378.2011.00874.x]
- 5 Laszewicz W, Iwańczak F, Iwańczak B; Task Force of the Polish Society of Gastroenterology; Task Force of the Polish Society of Gastroenterology. Seroprevalence of *Helicobacter pylori* infection in Polish children and adults depending on socioeconomic status and living conditions. *Adv Med Sci* 2014; **59**: 147-150 [PMID: 24797992 DOI: 10.1016/j.advms.2014.01.003]
- 6 Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. *Lancet* 1983; **1**: 1273-1275 [PMID: 6134060 DOI: 10.1016/S0140-6736(83)92719-8]
- 7 Wroblewski LE, Peek RM. *Helicobacter pylori*, Cancer, and the Gastric Microbiota. *Adv Exp Med Biol* 2016; **908**: 393-408 [PMID: 27573782 DOI: 10.1007/978-3-319-41388-4\_19]
- 8 Eaton KA, Morgan DR, Krakowka S. Motility as a factor in the colonisation of gnotobiotic piglets by *Helicobacter pylori*. *J Med Microbiol* 1992; **37**: 123-127 [PMID: 1629897 DOI: 10.1099/00222615-37-2-123]
- 9 Alm RA, Bina J, Andrews BM, Doig P, Hancock RE, Trust TJ. Comparative genomics of *Helicobacter pylori*: Analysis of the outer membrane protein families. *Infect Immun* 2000; **68**: 4155-4168 [PMID: 10858232 DOI: 10.1128/iai.68.7.4155-4168.2000]
- 10 Camilo V, Sugiyama T, Touati E. Pathogenesis of *Helicobacter pylori* infection. *Helicobacter* 2017; **22** Suppl 1 [PMID: 28891130 DOI: 10.1111/hel.12405]
- 11 Fischer W. Assembly and molecular mode of action of the *Helicobacter pylori* Cag type IV secretion apparatus. *FEBS J* 2011; **278**: 1203-1212 [PMID: 21352490 DOI: 10.1111/j.1742-4658.2011.08036.x]
- 12 Boquet P, Ricci V. Intoxication strategy of *Helicobacter pylori* VacA toxin. *Trends Microbiol* 2012; **20**: 165-174 [PMID: 22364673 DOI: 10.1016/j.tim.2012.01.008]
- 13 Lu H, Hsu PI, Graham DY, Yamaoka Y. Duodenal ulcer promoting gene of *Helicobacter pylori*. *Gastroenterology* 2005; **128**: 833-848 [PMID: 15825067 DOI: 10.1053/j.gastro.2005.01.009]
- 14 Yamaoka Y, Kwon DH, Graham DY. A M(r) 34,000 proinflammatory outer membrane protein (oipA) of *Helicobacter pylori*. *Proc Natl Acad Sci U S A* 2000; **97**: 7533-7538 [PMID: 10852959 DOI: 10.1073/pnas.130079797]
- 15 Shibayama K, Wachino J, Arakawa Y, Saidijam M, Rutherford NG, Henderson PJ. Metabolism of glutamine and glutathione via gamma-glutamyltranspeptidase and glutamate transport in *Helicobacter pylori*: Possible significance in the pathophysiology of the organism. *Mol Microbiol* 2007; **64**: 396-406 [PMID: 17381553 DOI: 10.1111/j.1365-2958.2007.05661.x]
- 16 Bamford KB, Fan X, Crowe SE, Leary JF, Gourley WK, Luthra GK, Brooks EG, Graham DY, Reyes VE, Ernst PB. Lymphocytes in the human gastric mucosa during *Helicobacter pylori* have a T helper cell 1 phenotype. *Gastroenterology* 1998; **114**: 482-492 [PMID: 9496938 DOI: 10.1016/S0016-5085(98)70531-1]
- 17 Malfertheiner P, Venerito M, Schulz C. *Helicobacter pylori* Infection: New Facts in Clinical Management. *Curr Treat Options Gastroenterol* 2018; **16**: 605-615 [PMID: 30415359 DOI: 10.1007/s11938-018-0209-8]
- 18 Abadi AT, Kusters JG. Management of *Helicobacter pylori* infections. *BMC Gastroenterol* 2016; **16**: 94 [PMID: 27520775 DOI: 10.1186/s12876-016-0496-2]
- 19 Patel SK, Pratap CB, Jain AK, Gulati AK, Nath G. Diagnosis of *Helicobacter pylori*: What should be the gold standard? *World J Gastroenterol* 2014; **20**: 12847-12859 [PMID: 25278682 DOI: 10.3748/wjg.v20.i36.12847]
- 20 Safavi M, Sabourian R, Foroumadi A. Treatment of *Helicobacter pylori* infection: Current and future insights. *World J Clin Cases* 2016; **4**: 5-19 [PMID: 26798626 DOI: 10.12998/wjcc.v4.i1.5]
- 21 Federico A, Gravina AG, Miranda A, Loguercio C, Romano M. Eradication of *Helicobacter pylori* infection: Which regimen first? *World J Gastroenterol* 2014; **20**: 665-672 [PMID: 24574740 DOI: 10.3748/wjg.v20.i3.665]
- 22 Ayala G, Escobedo-Hinojosa WI, de la Cruz-Herrera CF, Romero I. Exploring alternative treatments for *Helicobacter pylori* infection. *World J Gastroenterol* 2014; **20**: 1450-1469 [PMID: 24587621 DOI: 10.3748/wjg.v20.i6.1450]
- 23 Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DL. *Manual of clinical microbiology*. 10th ed. American Society for Microbiology 2011; 900-915 [DOI: 10.1128/9781555816728]

- 24 **Ottemann KM**, Lowenthal AC. *Helicobacter pylori* uses motility for initial colonization and to attain robust infection. *Infect Immun* 2002; **70**: 1984-1990 [PMID: [11895962](#) DOI: [10.1128/iai.70.4.1984-1990.2002](#)]
- 25 **Gu H**. Role of Flagella in the Pathogenesis of *Helicobacter pylori*. *Curr Microbiol* 2017; **74**: 863-869 [PMID: [28444418](#) DOI: [10.1007/s00284-017-1256-4](#)]
- 26 **Clyne M**, Ocroinin T, Suerbaum S, Josenhans C, Drumm B. Adherence of isogenic flagellum-negative mutants of *Helicobacter pylori* and *Helicobacter mustelae* to human and ferret gastric epithelial cells. *Infect Immun* 2000; **68**: 4335-4339 [PMID: [10858255](#) DOI: [10.1128/iai.68.7.4335-4339.2000](#)]
- 27 **Eaton KA**, Suerbaum S, Josenhans C, Krakowka S. Colonization of gnotobiotic piglets by *Helicobacter pylori* deficient in two flagellin genes. *Infect Immun* 1996; **64**: 2445-2448 [PMID: [8698465](#) DOI: [10.1016/0167-5699\(96\)80795-X](#)]
- 28 **Kim JS**, Chang JH, Chung SI, Yum JS. Molecular cloning and characterization of the *Helicobacter pylori* flhD gene, an essential factor in flagellar structure and motility. *J Bacteriol* 1999; **181**: 6969-6976 [PMID: [10559162](#) DOI: [10.1111/j.1755-3768.1923.tb03128.x](#)]
- 29 **Worku ML**, Karim QN, Spencer J, Sidebotham RL. Chemotactic response of *Helicobacter pylori* to human plasma and bile. *J Med Microbiol* 2004; **53**: 807-811 [PMID: [15272070](#) DOI: [10.1099/jmm.0.45636-0](#)]
- 30 **Mizote T**, Yoshiyama H, Nakazawa T. Urease-independent chemotactic responses of *Helicobacter pylori* to urea, urease inhibitors, and sodium bicarbonate. *Infect Immun* 1997; **65**: 1519-1521 [PMID: [9119496](#) DOI: [10.1016/S0928-8244\(97\)00015-1](#)]
- 31 **Alm RA**, Ling LS, Moir DT, King BL, Brown ED, Doig PC, Smith DR, Noonan B, Guild BC, deJonge BL, Carmel G, Tummino PJ, Caruso A, Uria-Nickelsen M, Mills DM, Ives C, Gibson R, Merberg D, Mills SD, Jiang Q, Taylor DE, Vovis GF, Trust TJ. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen *Helicobacter pylori*. *Nature* 1999; **397**: 176-180 [PMID: [9923682](#) DOI: [10.1038/16495](#)]
- 32 **Aizawa SI**, Harwood CS, Kadner RJ. Signaling components in bacterial locomotion and sensory reception. *J Bacteriol* 2000; **182**: 1459-1471 [PMID: [10692349](#) DOI: [10.1128/jb.182.6.1459-1471.2000](#)]
- 33 **Becker KW**, Skaar EP. Metal limitation and toxicity at the interface between host and pathogen. *FEMS Microbiol Rev* 2014; **38**: 1235-1249 [PMID: [25211180](#) DOI: [10.1111/1574-6976.12087](#)]
- 34 **Eaton KA**, Brooks CL, Morgan DR, Krakowka S. Essential role of urease in pathogenesis of gastritis induced by *Helicobacter pylori* in gnotobiotic piglets. *Infect Immun* 1991; **59**: 2470-2475 [PMID: [2050411](#) DOI: [10.1002/ps.2016](#)]
- 35 **Olson JW**, Maier RJ. Molecular hydrogen as an energy source for *Helicobacter pylori*. *Science* 2002; **298**: 1788-1790 [PMID: [12459589](#) DOI: [10.1126/science.1077123](#)]
- 36 **Kalali B**, Mejias-Luque R, Javaheri A, Gerhard M. H. *pylori* virulence factors: Influence on immune system and pathology. *Mediators Inflamm* 2014; **2014**: 426309 [PMID: [24587595](#) DOI: [10.1155/2014/426309](#)]
- 37 **Oliveira AG**, Santos A, Guerra JB, Rocha GA, Rocha AM, Oliveira CA, Cabral MM, Nogueira AM, Queiroz DM. babA2- and cagA-positive *Helicobacter pylori* strains are associated with duodenal ulcer and gastric carcinoma in Brazil. *J Clin Microbiol* 2003; **41**: 3964-3966 [PMID: [12904430](#) DOI: [10.1128/JCM.41.8.3964-3966.2003](#)]
- 38 **Björnham O**, Bugaytsova J, Borén T, Schedin S. Dynamic force spectroscopy of the *Helicobacter pylori* BabA-Lewis b binding. *Biophys Chem* 2009; **143**: 102-105 [PMID: [19344994](#) DOI: [10.1016/j.bpc.2009.03.007](#)]
- 39 **Mahdavi J**, Söndén B, Hurtig M, Olfat FO, Forsberg L, Roche N, Angstrom J, Larsson T, Teneberg S, Karlsson KA, Altraja S, Wadström T, Kersulyte D, Berg DE, Dubois A, Petersson C, Magnusson KE, Norberg T, Lindh F, Lundskog BB, Arnqvist A, Hammarström L, Borén T. *Helicobacter pylori* SabA adhesin in persistent infection and chronic inflammation. *Science* 2002; **297**: 573-578 [PMID: [12142529](#) DOI: [10.1126/science.1069076](#)]
- 40 **Javaheri A**, Kruse T, Moonens K, Mejias-Luque R, Debraekeleer A, Asche CI, Tegtmeyer N, Kalali B, Bach NC, Sieber SA, Hill DJ, Königer V, Hauck CR, Moskalenko R, Haas R, Busch DH, Klaile E, Slevogt H, Schmidt A, Backert S, Remaut H, Singer BB, Gerhard M. *Helicobacter pylori* adhesin HopQ engages in a virulence-enhancing interaction with human CEACAMs. *Nat Microbiol* 2016; **2**: 16189 [PMID: [27748768](#) DOI: [10.1038/nmicrobiol.2016.189](#)]
- 41 **Königer V**, Holsten L, Harrison U, Busch B, Loell E, Zhao Q, Bonsor DA, Roth A, Kengmo-Tchoupa A, Smith SI, Mueller S, Sundberg EJ, Zimmermann W, Fischer W, Hauck CR, Haas R. *Helicobacter pylori* exploits human CEACAMs via HopQ for adherence and translocation of CagA. *Nat Microbiol* 2016; **2**: 16188 [PMID: [27748756](#) DOI: [10.1038/nmicrobiol.2016.188](#)]
- 42 **Zhao Q**, Busch B, Jiménez-Soto LF, Ishikawa-Ankerhold H, Massberg S, Terradot L, Fischer W, Haas R. Integrin but not CEACAM receptors are dispensable for *Helicobacter pylori* CagA translocation. *PLoS Pathog* 2018; **14**: e1007359 [PMID: [30365569](#) DOI: [10.1371/journal.ppat.1007359](#)]
- 43 **Tsutsumi R**, Higashi H, Higuchi M, Okada M, Hatakeyama M. Attenuation of *Helicobacter pylori* CagA x SHP-2 signaling by interaction between CagA and C-terminal Src kinase. *J Biol Chem* 2003; **278**: 3664-3670 [PMID: [12446738](#) DOI: [10.1074/jbc.M208155200](#)]
- 44 **Suarez G**, Romero-Gallo J, Sierra JC, Piazzuelo MB, Krishna US, Gomez MA, Wilson KT, Peek RM. Genetic Manipulation of *Helicobacter pylori* Virulence Function by Host Carcinogenic Phenotypes. *Cancer Res* 2017; **77**: 2401-2412 [PMID: [28209611](#) DOI: [10.1158/0008-5472.CAN-16-2922](#)]
- 45 **Kanada R**, Uchida T, Tsukamoto Y, Nguyen LT, Hijiya N, Matsuura K, Kodama M, Okimoto T, Murakami K, Fujioka T, Yanagisawa S, Moriyama M. Genotyping of the cagA gene of *Helicobacter pylori* on immunohistochemistry with East Asian CagA-specific antibody. *Pathol Int* 2008; **58**: 218-225 [PMID: [18324914](#) DOI: [10.1111/j.1440-1827.2008.02214.x](#)]
- 46 **Yamaoka Y**, Osato MS, Sepulveda AR, Gutierrez O, Figura N, Kim JG, Kodama T, Kashima K, Graham DY. Molecular epidemiology of *Helicobacter pylori*: Separation of H. pylori from East Asian and non-Asian countries. *Epidemiol Infect* 2000; **124**: 91-96 [PMID: [10722135](#) DOI: [10.1017/s0950268899003209](#)]
- 47 **Basso D**, Zamboni CF, Letley DP, Stranges A, Marchet A, Rhead JL, Schiavon S, Guariso G, Ceroti M, Nitti D, Rugge M, Plebani M, Atherton JC. Clinical relevance of *Helicobacter pylori* cagA and vacA gene polymorphisms. *Gastroenterology* 2008; **135**: 91-99 [PMID: [18474244](#) DOI: [10.1053/j.gastro.2008.03.041](#)]
- 48 **Queiroz DM**, Silva CI, Goncalves MH, Braga-Neto MB, Fialho AB, Fialho AM, Rocha GA, Rocha AM, Batista SA, Guerrant RL, Lima AA, Braga LL. Higher frequency of cagA EPIYA-C phosphorylation sites in H. pylori strains from first-degree relatives of gastric cancer patients. *BMC Gastroenterol* 2012; **12**: 107

- [PMID: 22891666 DOI: 10.1186/1471-230X-12-107]
- 49 **Higashi H**, Tsutsumi R, Muto S, Sugiyama T, Azuma T, Asaka M, Hatakeyama M. SHP-2 tyrosine phosphatase as an intracellular target of *Helicobacter pylori* CagA protein. *Science* 2002; **295**: 683-686 [PMID: 11743164 DOI: 10.1126/science.1067147]
  - 50 **Atherton JC**, Peek RM, Tham KT, Cover TL, Blaser MJ. Clinical and pathological importance of heterogeneity in vacA, the vacuolating cytotoxin gene of *Helicobacter pylori*. *Gastroenterology* 1997; **112**: 92-99 [PMID: 8978347 DOI: 10.1016/S0016-5085(97)70223-3]
  - 51 **Djekic A**, Müller A. The Immunomodulator VacA Promotes Immune Tolerance and Persistent *Helicobacter pylori* Infection through Its Activities on T-Cells and Antigen-Presenting Cells. *Toxins (Basel)* 2016; **8**: pii: E187 [PMID: 27322319 DOI: 10.3390/toxins8060187]
  - 52 **Yamaoka Y**. Roles of the plasticity regions of *Helicobacter pylori* in gastroduodenal pathogenesis. *J Med Microbiol* 2008; **57**: 545-553 [PMID: 18436586 DOI: 10.1099/jmm.0.2008/000570-0]
  - 53 **Queiroz DM**, Rocha GA, Rocha AM, Moura SB, Saraiva IE, Gomes LI, Soares TF, Melo FF, Cabral MM, Oliveira CA. dupA polymorphisms and risk of *Helicobacter pylori*-associated diseases. *Int J Med Microbiol* 2011; **301**: 225-228 [PMID: 21050811 DOI: 10.1016/j.jimm.2010.08.019]
  - 54 **Farzi N**, Yadegar A, Aghdaei HA, Yamaoka Y, Zali MR. Genetic diversity and functional analysis of oipA gene in association with other virulence factors among *Helicobacter pylori* isolates from Iranian patients with different gastric diseases. *Infect Genet Evol* 2018; **60**: 26-34 [PMID: 29452293 DOI: 10.1016/j.meegid.2018.02.017]
  - 55 **Miftahussurur M**, Yamaoka Y, Graham DY. *Helicobacter pylori* as an oncogenic pathogen, revisited. *Expert Rev Mol Med* 2017; **19**: e4 [PMID: 28322182 DOI: 10.1017/erm.2017.4]
  - 56 **Liu J**, He C, Chen M, Wang Z, Xing C, Yuan Y. Association of presence/absence and on/off patterns of *Helicobacter pylori* oipA gene with peptic ulcer disease and gastric cancer risks: A meta-analysis. *BMC Infect Dis* 2013; **13**: 555 [PMID: 24256489 DOI: 10.1186/1471-2334-13-555]
  - 57 **Sallas ML**, Dos Santos MP, Orcini WA, David ÉB, Perquetti RL, Payão SLM, Rasmussen LT. Status (on/off) of oipA gene: Their associations with gastritis and gastric cancer and geographic origins. *Arch Microbiol* 2019; **201**: 93-97 [PMID: 30255200 DOI: 10.1007/s00203-018-1580-5]
  - 58 **Franco AT**, Johnston E, Krishna U, Yamaoka Y, Israel DA, Nagy TA, Wroblewski LE, Piazuelo MB, Correa P, Peek RM. Regulation of gastric carcinogenesis by *Helicobacter pylori* virulence factors. *Cancer Res* 2008; **68**: 379-387 [PMID: 18199531 DOI: 10.1158/0008-5472.CAN-07-0824]
  - 59 **Shibayama K**, Kamachi K, Nagata N, Yagi T, Nada T, Doi Y, Shibata N, Yokoyama K, Yamane K, Kato H, Iinuma Y, Arakawa Y. A novel apoptosis-inducing protein from *Helicobacter pylori*. *Mol Microbiol* 2003; **47**: 443-451 [PMID: 12519194 DOI: 10.1046/j.1365-2958.2003.03305.x]
  - 60 **Kim KM**, Lee SG, Kim JM, Kim DS, Song JY, Kang HL, Lee WK, Cho MJ, Rhee KH, Youn HS, Baik SC. *Helicobacter pylori* gamma-glutamyltranspeptidase induces cell cycle arrest at the G1-S phase transition. *J Microbiol* 2010; **48**: 372-377 [PMID: 20571956 DOI: 10.1007/s12275-010-9293-8]
  - 61 **Schmees C**, Prinz C, Treptau T, Rad R, Hengst L, Voland P, Bauer S, Brenner L, Schmid RM, Gerhard M. Inhibition of T-cell proliferation by *Helicobacter pylori* gamma-glutamyl transpeptidase. *Gastroenterology* 2007; **132**: 1820-1833 [PMID: 17484877 DOI: 10.1053/j.gastro.2007.02.031]
  - 62 **Oertli M**, Noben M, Engler DB, Semper RP, Reuter S, Maxeiner J, Gerhard M, Taube C, Müller A. *Helicobacter pylori*  $\gamma$ -glutamyl transpeptidase and vacuolating cytotoxin promote gastric persistence and immune tolerance. *Proc Natl Acad Sci U S A* 2013; **110**: 3047-3052 [PMID: 23382221 DOI: 10.1073/pnas.1211248110]
  - 63 **Gong M**, Ling SS, Lui SY, Yeoh KG, Ho B. *Helicobacter pylori* gamma-glutamyl transpeptidase is a pathogenic factor in the development of peptic ulcer disease. *Gastroenterology* 2010; **139**: 564-573 [PMID: 20347814 DOI: 10.1053/j.gastro.2010.03.050]
  - 64 **Yoshikawa T**, Naito Y. The role of neutrophils and inflammation in gastric mucosal injury. *Free Radic Res* 2000; **33**: 785-794 [PMID: 11237100 DOI: 10.1080/10715760000301301]
  - 65 **Crabtree JE**, Mahony MJ, Taylor JD, Heatley RV, Littlewood JM, Tompkins DS. Immune responses to *Helicobacter pylori* in children with recurrent abdominal pain. *J Clin Pathol* 1991; **44**: 768-771 [PMID: 1918408 DOI: 10.1136/jcp.44.9.768]
  - 66 **Nagashima H**, Iwatani S, Cruz M, Jiménez Abreu JA, Uchida T, Mahachai V, Vilaichone RK, Graham DY, Yamaoka Y. Toll-like Receptor 10 in *Helicobacter pylori* Infection. *J Infect Dis* 2015; **212**: 1666-1676 [PMID: 25977263 DOI: 10.1093/infdis/jiv270]
  - 67 **Smith SM**. Role of Toll-like receptors in *Helicobacter pylori* infection and immunity. *World J Gastrointest Pathophysiol* 2014; **5**: 133-146 [PMID: 25133016 DOI: 10.4291/wjgp.v5.i3.133]
  - 68 **Smith MF**, Mitchell A, Li G, Ding S, Fitzmaurice AM, Ryan K, Crowe S, Goldberg JB. Toll-like receptor (TLR) 2 and TLR5, but not TLR4, are required for *Helicobacter pylori*-induced NF-kappa B activation and chemokine expression by epithelial cells. *J Biol Chem* 2003; **278**: 32552-32560 [PMID: 12807870 DOI: 10.1074/jbc.M305536200]
  - 69 **Alandiyyany MN**, Croxall NJ, Grove JI, Delahay RM. A role for the tfs3 ICE-encoded type IV secretion system in pro-inflammatory signalling by the *Helicobacter pylori* Ser/Thr kinase, CtkA. *PLoS One* 2017; **12**: e0182144 [PMID: 28759055 DOI: 10.1371/journal.pone.0182144]
  - 70 **Wilson KT**, Ramanujam KS, Mobley HL, Musselman RF, James SP, Meltzer SJ. *Helicobacter pylori* stimulates inducible nitric oxide synthase expression and activity in a murine macrophage cell line. *Gastroenterology* 1996; **111**: 1524-1533 [PMID: 8942731 DOI: 10.1016/S0016-5085(96)70014-8]
  - 71 **Lundgren A**, Suri-Payer E, Enarsson K, Svennerholm AM, Lundin BS. *Helicobacter pylori*-specific CD4+ CD25high regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. *Infect Immun* 2003; **71**: 1755-1762 [PMID: 12654789 DOI: 10.1128/IAI.71.4.1755-1762.2003]
  - 72 **Crabtree JE**, Shallcross TM, Heatley RV, Wyatt JI. Mucosal tumour necrosis factor alpha and interleukin-6 in patients with *Helicobacter pylori* associated gastritis. *Gut* 1991; **32**: 1473-1477 [PMID: 1773951 DOI: 10.1136/gut.32.12.1473]
  - 73 **Lindholm C**, Quiding-Järbrink M, Lönnroth H, Hamlet A, Svennerholm AM. Local cytokine response in *Helicobacter pylori*-infected subjects. *Infect Immun* 1998; **66**: 5964-5971 [PMID: 9826379 DOI: 10.1111/j.1574-695X.1998.tb01224.x]
  - 74 **Freire de Melo F**, Rocha AM, Rocha GA, Pedrosa SH, de Assis Batista S, Fonseca de Castro LP, Carvalho SD, Bittencourt PF, de Oliveira CA, Corrêa-Oliveira R, Magalhães Queiroz DM. A regulatory instead of an IL-17 T response predominates in *Helicobacter pylori*-associated gastritis in children. *Microbes Infect* 2012; **14**: 341-347 [PMID: 22155622 DOI: 10.1016/j.micinf.2011.11.008]
  - 75 **Nurgalieva ZZ**, Conner ME, Opekun AR, Zheng CQ, Elliott SN, Ernst PB, Osato M, Estes MK, Graham DY. B-cell and T-cell immune responses to experimental *Helicobacter pylori* infection in humans. *Infect*

- Immun* 2005; **73**: 2999-3006 [PMID: 15845507 DOI: 10.1128/IAI.73.5.2999-3006.2005]
- 76 **Mattsson A**, Quiding-Järbrink M, Lönroth H, Hamlet A, Ahlstedt I, Svennerholm A. Antibody-secreting cells in the stomachs of symptomatic and asymptomatic *Helicobacter pylori*-infected subjects. *Infect Immun* 1998; **66**: 2705-2712 [PMID: 9596737 DOI: 10.1111/j.1574-695X.1998.tb01162.x]
- 77 **Perez-Perez GI**, Dworkin BM, Chodos JE, Blaser MJ. Campylobacter pylori antibodies in humans. *Ann Intern Med* 1988; **109**: 11-17 [PMID: 3288028 DOI: 10.7326/0003-4819-109-1-11]
- 78 **Suerbaum S**, Michetti P. *Helicobacter pylori* infection. *N Engl J Med* 2002; **347**: 1175-1186 [PMID: 12374879 DOI: 10.1056/NEJMra020542]
- 79 **Malfertheiner P**, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European *Helicobacter* Study Group. Management of *Helicobacter pylori* infection--the Maastricht IV/ Florence Consensus Report. *Gut* 2012; **61**: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]
- 80 **Liu L**, Gao H, Wang H, Yu W, Zhu K, Zhang Y, Guo J. Comparison of Esophageal Function Tests to Investigate the Effect of *Helicobacter Pylori* Infection on Gastroesophageal Reflux Disease (GERD). *Med Sci Monit* 2018; **24**: 4791-4797 [PMID: 29992917 DOI: 10.12659/MSM.908051]
- 81 **Gravina AG**, Zagari RM, De Musis C, Romano L, Loguercio C, Romano M. *Helicobacter pylori* and extragastric diseases: A review. *World J Gastroenterol* 2018; **24**: 3204-3221 [PMID: 30090002 DOI: 10.3748/wjg.v24.i29.3204]
- 82 **Wang YK**, Kuo FC, Liu CJ, Wu MC, Shih HY, Wang SS, Wu JY, Kuo CH, Huang YK, Wu DC. Diagnosis of *Helicobacter pylori* infection: Current options and developments. *World J Gastroenterol* 2015; **21**: 11221-11235 [PMID: 26523098 DOI: 10.3748/wjg.v21.i40.11221]
- 83 **Al-Moayad EE**, Alghalibi SM, Al-Shamahy HA, Nasher AT, Al-Hebshi NN. Normalized real-time PCR for diagnosis of *H. pylori* infection. *Qatar Med J* 2014; **2014**: 123-129 [PMID: 25745602 DOI: 10.5339/qmj.2014.19]
- 84 **Costamagna G**, Zullo A, Bizzotto A, Spada C, Hassan C, Riccioni ME, Marmo C, Strangio G, Di Rienzo TA, Cammarota G, Gasbarrini A, Repici A. Real-time diagnosis of *H. pylori* infection during endoscopy: Accuracy of an innovative tool (EndoFaster). *United European Gastroenterol J* 2016; **4**: 339-342 [PMID: 27403299 DOI: 10.1177/2050640615610021]
- 85 **Cutler AF**, Prasad VM. Long-term follow-up of *Helicobacter pylori* serology after successful eradication. *Am J Gastroenterol* 1996; **91**: 85-88 [PMID: 8561150]
- 86 **Coelho LG**, Sant'Ana CR, Oliveira RB, Cezar RCE, Araujo ACC, Silva RCTD, Trindade OR, Coelho MC, Ferrioli E, Bendassolli JA. Performance of the <sup>13</sup>C-urea breath test for the diagnosis of *H. pylori* infection using a substrate synthesized in Brazil: A preliminary study. *Clinics (Sao Paulo)* 2018; **73**: e16553 [PMID: 29898005 DOI: 10.6061/clinics/2018/e16-553]
- 87 **Shimoyama T**. Stool antigen tests for the management of *Helicobacter pylori* infection. *World J Gastroenterol* 2013; **19**: 8188-8191 [PMID: 24363508 DOI: 10.3748/wjg.v19.i45.8188]
- 88 **Gong Y**, Li Q, Yuan Y. Accuracy of testing for anti-*Helicobacter pylori* IgG in urine for *H. pylori* infection diagnosis: A systematic review and meta-analysis. *BMJ Open* 2017; **7**: e013248 [PMID: 28455424 DOI: 10.1136/bmjopen-2016-013248]
- 89 **Khalifeh Gholi M**, Kalali B, Formichella L, Göttner G, Shamsipour F, Zarnani AH, Hosseini M, Busch DH, Shirazi MH, Gerhard M. *Helicobacter pylori* FlhD protein is a highly sensitive and specific marker for serologic diagnosis of *H. pylori* infection. *Int J Med Microbiol* 2013; **303**: 618-623 [PMID: 24103649 DOI: 10.1016/j.ijmm.2013.08.005]
- 90 **Malfertheiner P**, Megraud F, O'Morain C, Bell D, Bianchi Porro G, Deltenre M, Forman D, Gasbarrini G, Jaup B, Misiewicz JJ, Pajares J, Quina M, Rauws E. Current European concepts in the management of *Helicobacter pylori* infection--the Maastricht Consensus Report. The European *Helicobacter Pylori* Study Group (EHPSG). *Eur J Gastroenterol Hepatol* 1997; **9**: 1-2 [PMID: 9031888 DOI: 10.1097/00042737-199701000-00002]
- 91 **Wani FA**, Bashir G, Khan MA, Zargar SA, Rasool Z, Qadri Q. Antibiotic resistance in *Helicobacter pylori*: A mutational analysis from a tertiary care hospital in Kashmir, India. *Indian J Med Microbiol* 2018; **36**: 265-272 [PMID: 30084422 DOI: 10.4103/ijmm.IJMM\_18\_19]
- 92 **Hu Y**, Zhu Y, Lu NH. Novel and Effective Therapeutic Regimens for *Helicobacter pylori* in an Era of Increasing Antibiotic Resistance. *Front Cell Infect Microbiol* 2017; **7**: 168 [PMID: 28529929 DOI: 10.3389/fcimb.2017.00168]
- 93 **Chey WD**, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of *Helicobacter pylori* Infection. *Am J Gastroenterol* 2017; **112**: 212-239 [PMID: 28071659 DOI: 10.1038/ajg.2016.563]
- 94 **Hsu PI**, Wu DC, Wu JY, Graham DY. Modified sequential *Helicobacter pylori* therapy: Proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days. *Helicobacter* 2011; **16**: 139-145 [PMID: 21435092 DOI: 10.1111/j.1523-5378.2011.00828.x]
- 95 **Ierardi E**, Giorgio F, Iannone A, Losurdo G, Principi M, Barone M, Pisani A, Di Leo A. Noninvasive molecular analysis of *Helicobacter pylori*: Is it time for tailored first-line therapy? *World J Gastroenterol* 2017; **23**: 2453-2458 [PMID: 28465629 DOI: 10.3748/wjg.v23.i14.2453]
- 96 **Ierardi E**, Giorgio F, Losurdo G, Di Leo A, Principi M. How antibiotic resistances could change *Helicobacter pylori* treatment: A matter of geography? *World J Gastroenterol* 2013; **19**: 8168-8180 [PMID: 24363506 DOI: 10.3748/wjg.v19.i45.8168]
- 97 **Zagari RM**, Romiti A, Ierardi E, Gravina AG, Panarese A, Grande G, Savarino E, Maconi G, Stasi E, Eusebi LH, Farinati F, Conigliaro R, Bazzoli F, Romano M. The "three-in-one" formulation of bismuth quadruple therapy for *Helicobacter pylori* eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice. *Helicobacter* 2018; **23**: e12502 [PMID: 29924430 DOI: 10.1111/hel.12502]
- 98 **Zhu XY**, Liu F. Probiotics as an adjuvant treatment in *Helicobacter pylori* eradication therapy. *J Dig Dis* 2017; **18**: 195-202 [PMID: 28294543 DOI: 10.1111/1751-2980.12466]
- 99 **Dang Y**, Reinhardt JD, Zhou X, Zhang G. The effect of probiotics supplementation on *Helicobacter pylori* eradication rates and side effects during eradication therapy: A meta-analysis. *PLoS One* 2014; **9**: e111030 [PMID: 25365320 DOI: 10.1371/journal.pone.0111030]
- 100 **Lv Z**, Wang B, Zhou X, Wang F, Xie Y, Zheng H, Lv N. Efficacy and safety of probiotics as adjuvant agents for *Helicobacter pylori* infection: A meta-analysis. *Exp Ther Med* 2015; **9**: 707-716 [PMID: 25667617 DOI: 10.3892/etm.2015.2174]
- 101 **Sutton P**, Boag JM. Status of vaccine research and development for *Helicobacter pylori*. *Vaccine* 2018; pii: S0264-410X(18)30017-3 [PMID: 29627231 DOI: 10.1016/j.vaccine.2018.01.001]

- 102 **Zeng M**, Mao XH, Li JX, Tong WD, Wang B, Zhang YJ, Guo G, Zhao ZJ, Li L, Wu DL, Lu DS, Tan ZM, Liang HY, Wu C, Li DH, Luo P, Zeng H, Zhang WJ, Zhang JY, Guo BT, Zhu FC, Zou QM. Efficacy, safety, and immunogenicity of an oral recombinant *Helicobacter pylori* vaccine in children in China: A randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2015; **386**: 1457-1464 [PMID: 26142048 DOI: 10.1016/S0140-6736(15)60310-5]
- 103 **Wang B**, Pan X, Wang H, Zhou Y, Zhu J, Yang J, Li W. Immunological response of recombinant H. pylori multi-epitope vaccine with different vaccination strategies. *Int J Clin Exp Pathol* 2014; **7**: 6559-6566 [PMID: 25400734]
- 104 **Milani M**, Sharifi Y, Rahmati-Yamchi M, Somi MH, Akbarzadeh A. Immunology and vaccines and nanovaccines for *Helicobacter pylori* infection. *Expert Rev Vaccines* 2015; **14**: 833-840 [PMID: 25645086 DOI: 10.1586/14760584.2015.1008460]
- 105 **Rad R**, Gerhard M, Lang R, Schöninger M, Rösch T, Schepp W, Becker I, Wagner H, Prinz C. The *Helicobacter pylori* blood group antigen-binding adhesin facilitates bacterial colonization and augments a nonspecific immune response. *J Immunol* 2002; **168**: 3033-3041 [PMID: 11884476 DOI: 10.4049/jimmunol.168.6.3033]
- 106 **Sakamoto S**, Watanabe T, Tokumaru T, Takagi H, Nakazato H, Lloyd KO. Expression of Lewis<sup>a</sup>, Lewis<sup>b</sup>, Lewis<sup>x</sup>, Lewis<sup>y</sup>, sialyl-Lewis<sup>a</sup>, and sialyl-Lewis<sup>x</sup> blood group antigens in human gastric carcinoma and in normal gastric tissue. *Cancer Res* 1989; **49**: 745-752 [PMID: 2910493 DOI: 10.1016/0304-3835(89)90011-6]
- 107 **Walz A**, Odenbreit S, Mahdavi J, Borén T, Ruhl S. Identification and characterization of binding properties of *Helicobacter pylori* by glycoconjugate arrays. *Glycobiology* 2005; **15**: 700-708 [PMID: 15716466 DOI: 10.1093/glycob/cwi049]
- 108 **Lu H**, Wu JY, Beswick EJ, Ohno T, Odenbreit S, Haas R, Reyes VE, Kita M, Graham DY, Yamaoka Y. Functional and intracellular signaling differences associated with the *Helicobacter pylori* AlpAB adhesin from Western and East Asian strains. *J Biol Chem* 2007; **282**: 6242-6254 [PMID: 17202133 DOI: 10.1074/jbc.M611178200]
- 109 **Yamaoka Y**, Kikuchi S, el-Zimaity HM, Gutierrez O, Osato MS, Graham DY. Importance of *Helicobacter pylori* oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. *Gastroenterology* 2002; **123**: 414-424 [PMID: 12145793 DOI: 10.1053/gast.2002.34781]
- 110 **Gur C**, Maalouf N, Gerhard M, Singer BB, Emgård J, Temper V, Neuman T, Mandelboim O, Bachrach G. The *Helicobacter pylori* HopQ outer membrane protein inhibits immune cell activities. *Oncoimmunology* 2019; **8**: e1553487 [PMID: 30906650 DOI: 10.1080/2162402X.2018.1553487]
- 111 **Acio-Pizzarello CR**, Acio AA, Choi EJ, Bond K, Kim J, Kenan AC, Chen J, Forsyth MH. Determinants of the regulation of *Helicobacter pylori* adhesins include repeat sequences in both promoter and coding regions as well as the two-component system ArsRS. *J Med Microbiol* 2017; **66**: 798-807 [PMID: 28598306 DOI: 10.1099/jmm.0.000491]



Published By Baishideng Publishing Group Inc  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA  
Telephone: +1-925-2238242  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

